ATAD2 (E8Y7F) Rabbit mAb #50563

ATPase family AAA domain containing protein 2 (ATAD2) is an oncogenic protein that was originally identified as a coactivator for estrogen receptor (ESR1), and later identified as a coactivator for other transcription factors including c-Myc and E2F1, E2F2, and E2F3 proteins (1-4). ATAD2 is highly expressed and associated with poor prognosis in many types of cancer, including breast, uterine, colon, ovarian, stomach, non-small cell lung carcinoma, osteosarcoma, and cervical cancer (1,5-14). In cancer cells, overexpressed ATAD2 interacts with transcription factors and chromatin modifier proteins to induce the expression of genes that promote cell proliferation and inhibit apoptosis, ultimately promoting tumor growth (15,16). Indeed, knockdown of ATAD2 in pancreatic cancer cell lines has been shown to promote apoptosis, limit cell migration and invasion, and inhibit anchorage-independent growth (17). ATAD2 is a member of the ATPases associated with various cellular activities (AAA) family of proteins and contains a functional AAA domain in its central region, as well as a bromodomain near the C-terminus. The bromodomain binds to acetylated lysine residues on histone proteins, targeting ATAD2 protein to areas of active transcription, where it modulates chromatin structure and recruits additional transcription factors (18,19). Current efforts are underway to better characterize and develop inhibitors to the ATAD2 bromodomain for the treatment of various cancers (16,20-23).